FDA D.I.S.C.O. Burst Edition: FDA approval of Tibsovo (ivosidenib) for patients with relapsed or refractory myelodysplastic syndromes with a susceptible isocitrate dehydrogenase-1 mutation
0:00
3:30
FDA D.I.S.C.O. Burst Edition: FDA approval of Tibsovo (ivosidenib) for patients with relapsed or refractory myelodysplastic syndromes with a susceptible isocitrate dehydrogenase-1 mutation
Flere episoder fra "FDA Drug Information Soundcast in Clinical Oncology (D.I.S.C.O.)"
Gå ikke glip af nogen episoder af “FDA Drug Information Soundcast in Clinical Oncology (D.I.S.C.O.)” - abonnér på podcasten med gratisapp GetPodcast.